Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
USD 49.0
(0.0%)
USD 49.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.52 Billion EUR | 2.82% |
| 2022 | 2.45 Billion EUR | 70.96% |
| 2021 | 1.43 Billion EUR | -0.06% |
| 2020 | 1.43 Billion EUR | -10.85% |
| 2019 | 1.61 Billion EUR | 34.19% |
| 2018 | 1.19 Billion EUR | 16.58% |
| 2017 | 1.02 Billion EUR | 56.69% |
| 2016 | 656.8 Million EUR | 9.67% |
| 2015 | 598.89 Million EUR | 1.89% |
| 2014 | 587.8 Million EUR | 1.0% |
| 2013 | 581.99 Million EUR | 36.78% |
| 2012 | 425.49 Million EUR | 11.1% |
| 2011 | 382.98 Million EUR | 17.82% |
| 2010 | 325.06 Million EUR | 3.37% |
| 2009 | 314.48 Million EUR | -15.05% |
| 2008 | 370.2 Million EUR | 1.68% |
| 2007 | 364.07 Million EUR | 19.74% |
| 2006 | 304.04 Million EUR | -5.78% |
| 2005 | 322.7 Million EUR | 1.74% |
| 2004 | 317.17 Million EUR | 27.1% |
| 2003 | 249.54 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.46 Billion EUR | -2.3% |
| 2024 Q2 | 2.39 Billion EUR | -2.75% |
| 2023 FY | 2.52 Billion EUR | 2.82% |
| 2023 Q1 | 2.32 Billion EUR | -5.1% |
| 2023 Q2 | 2.59 Billion EUR | 11.67% |
| 2023 Q3 | 2.5 Billion EUR | -3.56% |
| 2023 Q4 | 2.52 Billion EUR | 0.61% |
| 2022 Q3 | 2.36 Billion EUR | -4.93% |
| 2022 FY | 2.45 Billion EUR | 70.96% |
| 2022 Q4 | 2.45 Billion EUR | 3.6% |
| 2022 Q1 | 2.19 Billion EUR | 52.9% |
| 2022 Q2 | 2.49 Billion EUR | 13.53% |
| 2021 Q3 | 1.48 Billion EUR | -4.07% |
| 2021 Q4 | 1.43 Billion EUR | -3.36% |
| 2021 FY | 1.43 Billion EUR | -0.06% |
| 2021 Q1 | 1.5 Billion EUR | 5.09% |
| 2021 Q2 | 1.54 Billion EUR | 2.59% |
| 2020 Q3 | 1.52 Billion EUR | -2.88% |
| 2020 Q4 | 1.43 Billion EUR | -5.73% |
| 2020 FY | 1.43 Billion EUR | -10.85% |
| 2020 Q1 | 1.57 Billion EUR | -1.88% |
| 2020 Q2 | 1.56 Billion EUR | -0.76% |
| 2019 FY | 1.61 Billion EUR | 34.19% |
| 2019 Q3 | 1.5 Billion EUR | 36.86% |
| 2019 Q2 | 1.09 Billion EUR | -4.91% |
| 2019 Q1 | 1.15 Billion EUR | -3.78% |
| 2019 Q4 | 1.61 Billion EUR | 7.16% |
| 2018 FY | 1.19 Billion EUR | 16.58% |
| 2018 Q3 | 1.07 Billion EUR | -1.49% |
| 2018 Q4 | 1.19 Billion EUR | 11.92% |
| 2018 Q2 | 1.08 Billion EUR | 4.71% |
| 2018 Q1 | 1.03 Billion EUR | 0.98% |
| 2017 Q2 | 778.77 Million EUR | 15.18% |
| 2017 FY | 1.02 Billion EUR | 56.69% |
| 2017 Q4 | 1.02 Billion EUR | 7.22% |
| 2017 Q3 | 959.82 Million EUR | 23.25% |
| 2017 Q1 | 676.15 Million EUR | 2.95% |
| 2016 FY | 656.8 Million EUR | 9.67% |
| 2016 Q4 | 656.8 Million EUR | 4.32% |
| 2016 Q3 | 629.61 Million EUR | -1.28% |
| 2016 Q2 | 637.78 Million EUR | 2.67% |
| 2016 Q1 | 621.22 Million EUR | 3.73% |
| 2015 Q2 | 608.67 Million EUR | -0.26% |
| 2015 Q4 | 598.89 Million EUR | 0.0% |
| 2015 Q3 | 598.86 Million EUR | -1.61% |
| 2015 Q1 | 610.23 Million EUR | 3.82% |
| 2015 FY | 598.89 Million EUR | 1.89% |
| 2014 Q1 | 606.54 Million EUR | 4.22% |
| 2014 FY | 587.8 Million EUR | 1.0% |
| 2014 Q4 | 587.8 Million EUR | -9.21% |
| 2014 Q3 | 647.41 Million EUR | 11.7% |
| 2014 Q2 | 579.59 Million EUR | -4.44% |
| 2013 Q4 | 581.99 Million EUR | 17.22% |
| 2013 Q2 | 479.55 Million EUR | -5.09% |
| 2013 Q1 | 505.29 Million EUR | 18.76% |
| 2013 FY | 581.99 Million EUR | 36.78% |
| 2013 Q3 | 496.5 Million EUR | 3.53% |
| 2012 Q1 | 398.5 Million EUR | 4.05% |
| 2012 Q2 | 371.97 Million EUR | -6.66% |
| 2012 Q3 | 380.38 Million EUR | 2.26% |
| 2012 FY | 425.49 Million EUR | 11.1% |
| 2012 Q4 | 425.49 Million EUR | 11.86% |
| 2011 Q3 | 426.12 Million EUR | 10.48% |
| 2011 Q4 | 382.98 Million EUR | -10.12% |
| 2011 Q1 | 388.6 Million EUR | 19.55% |
| 2011 Q2 | 385.71 Million EUR | -0.74% |
| 2011 FY | 382.98 Million EUR | 17.82% |
| 2010 Q1 | 297.96 Million EUR | -5.25% |
| 2010 FY | 325.06 Million EUR | 3.37% |
| 2010 Q2 | 299.72 Million EUR | 0.59% |
| 2010 Q3 | 292.09 Million EUR | -2.55% |
| 2010 Q4 | 325.06 Million EUR | 11.29% |
| 2009 Q4 | 314.48 Million EUR | 0.0% |
| 2009 FY | 314.48 Million EUR | -15.05% |
| 2008 FY | 370.2 Million EUR | 1.68% |
| 2007 FY | 364.07 Million EUR | 19.74% |
| 2006 FY | 304.04 Million EUR | -5.78% |
| 2005 FY | 322.7 Million EUR | 1.74% |
| 2004 FY | 317.17 Million EUR | 27.1% |
| 2003 FY | 249.54 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AstraZeneca PLC | 61.86 Billion USD | 95.924% |
| Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | 96.16% |
| CSPC Pharmaceutical Group Limited | 1.53 Billion USD | -63.769% |
| Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | -3628.894% |
| Novartis AG | 53.19 Billion USD | 95.259% |
| PT Kalbe Farma Tbk. | 255.94 Million USD | -885.283% |